{"nctId":"NCT01709409","briefTitle":"A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants","startDateStruct":{"date":"2013-03"},"conditions":["Respiratory Distress Syndrome"],"count":88,"armGroups":[{"label":"Curosurf (Group 1)","type":"EXPERIMENTAL","interventionNames":["Drug: Curosurf-Group1"]},{"label":"BLES (Group 2)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: BLES-group 2"]}],"interventions":[{"name":"Curosurf-Group1","otherNames":[]},{"name":"BLES-group 2","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Infants born between 24+0 and 31+6 weeks gestational age, admitted to the study centers\n2. Infants with RDS requiring intubation and surfactant therapy within 48 hours after birth\n\nExclusion Criteria:\n\n1. Any infant more than 48 hours of age\n2. Any infant with a pulmonary hemorrhage\n3. Any infant with life-threatening congenital anomaly or one that is considered non-viable\n4. Any infant on rescue high frequency ventilation\n5. Any infant known to require early intubation and ventilation for surgical treatment of a congenital anomaly\n6. Any infant with anomalies of the upper or lower airway or mandible precluding use of nCPAP\n7. Any infant born after prolonged premature rupture of membranes (\\<22 weeks GA or \\>28 days prior to delivery)\n8. A parent/LAR who is incapable of, or unwilling, to give consent\n9. Participation in another clinical trial of any placebo, drug, biological, or device conducted under the provisions of a protocol\n10. Any other reason as deemed significant by the Investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"24 Weeks","maximumAge":"31 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Objective of the Study is to Compare Between the Two Groups, the Number of Subjects Alive and Extubated at 48 Hours Post Surfactant Administration. Extubation","description":"1. rate on ventilator ≤40 per minute and\n2. mean airway pressure ≤ 10 cm H20 and\n3. fi02 ≤ 30%","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"To Compare the Duration of Respiratory Support, Extubation Failure Rates, Need for Additional Surfactant Doses, Adverse Events (During and Following Administration), Survival and Pulmonary Morbidities During Hospital Admission Between the Two Groups.","description":"1\\. Extubation failure","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Curosurf-01","description":"2\\. Duration of first intubation (in hours/days)","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Curosurf-01","description":"3\\. Total duration of respiratory support (ventilator and nCPAP) and total number of days of oxygen requirement","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Curosurf-01","description":"4\\. Number of doses of surfactant received","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Curosurf-01","description":"5\\. Adverse events during or after administration of surfactant","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Curosurf-01","description":"6\\. Bronchopulmonary dysplasia, defined as oxygen or respiratory support requirement at 36 weeks corrected GA","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Curosurf-01","description":"7\\. Mortality prior to discharge","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":42},"commonTop":["pulmonary interstitial emphysema"]}}}